First-line nanoparticle polymeric micellar paclitaxel with gemcitabine in metastatic pancreatic cancer: a single-arm, prospective, and exploratory study
Gastroenterology Report · 20.01.2026 · 14
DOI: 10.1093/gastro/goag034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gastroenterology Report, online erschienen am 01.05.2026. Verfasst von Nan Lyu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu, 210029, China. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Xisike Clinical Oncology Research Foundation, Young Scholars Fostering Fund of the First Affiliated Hospital with Nanjing Medical University, Center for Medical and Health Technology Development, National Health Commission.
Abstract (Originalsprache)
Background
Pancreatic cancer is one of the most lethal malignancies, with limited therapeutic options. In this exploratory trial, we aimed to evaluate the efficacy and safety of nanoparticle polymeric micellar paclitaxel (pm-Pac) combined with gemcitabine as first-line treatment for metastatic pancreatic cancer (mPC).
Methods
Twenty-one patients with histologically or cytologically confirmed mPC were enrolled in this study. The primary endpoint was progression-free survival (PFS). Meanwhile, the secondary endpoints included the objective response rate (ORR), overall survival, disease control rate (DCR), duration of response (DOR), and safety of combination therapy.
Results
The median PFS was 7.4 months (95% confidence interval [CI]: 5.4–9.4 months). The ORR and DCR were 52.4% (95% CI: 29.1%–75.7%) and 95.2% (95% CI: 85.3%–100%), respectively. Amongst patients who achieved partial response, the median DOR was 4.8 months (95% CI: 1.5–8.1 months). No treatment-related deaths were reported. Grade 3–4 adverse events (AEs) occurred in 81.0% of patients, with increased γ-glutamyltransferase levels (38.1%), neutropenia (33.3%), and leukocytopenia (28.6%) being the most frequent AEs. Low SERPINB3 and SERPINB4 expression was correlated with prolonged PFS, accompanied by the significant downregulation of gene sets involved in DNA replication, nonsense-mediated mRNA decay, and protein translation in long-PFS tumours. Tumour immune microenvironment analysis revealed that patients with short PFS had increased levels of common lymphoid progenitors and decreased populations of mature B and T lymphocytes.
Conclusions
The combination of pm-Pac and gemcitabine as first-line therapy for mPC exhibited favourable tolerability and clinical efficacy. However, larger randomized–controlled trials are needed to validate these preliminary findings. Trial Registration www.chictr.org.cn, ChiCTR2300078861
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu, 210029, China.
- Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, 211800, P. R. China.
- Pancreas Center, Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, 211100, P. R. China.
Förderung
- Beijing Xisike Clinical Oncology Research Foundation
- Young Scholars Fostering Fund of the First Affiliated Hospital with Nanjing Medical University
- Center for Medical and Health Technology Development, National Health Commission
Zitieren
APA
Lyu, N., Wang, Q., Jiang, K., Xu, D., Wu, Y., Zhang, K., Wei, J., Chen, J., Guo, F., Lu, Z., Xiao, B., Chen, G., Wu, J., Gao, W., Wang, Y., Wang, F., & Tu, M. (2026). First-line nanoparticle polymeric micellar paclitaxel with gemcitabine in metastatic pancreatic cancer: a single-arm, prospective, and exploratory study. Gastroenterology Report, 14. https://doi.org/10.1093/gastro/goag034
Vancouver
Lyu N, Wang Q, Jiang K, Xu D, Wu Y, Zhang K, et al. First-line nanoparticle polymeric micellar paclitaxel with gemcitabine in metastatic pancreatic cancer: a single-arm, prospective, and exploratory study. Gastroenterology Report. 2026;14. doi:10.1093/gastro/goag034
BibTeX
@article{Lyu2026,
author = {Lyu, Nan and Wang, Qianqian and Jiang, Kuirong and Xu, Dong and Wu, Yang and Zhang, Kai and Wei, Jishu and Chen, Jianmin and Guo, Feng and Lu, Zipeng and Xiao, Bin and Chen, Guosheng and Wu, Junli and Gao, Wentao and Wang, Yuqi and Wang, Fufeng and Tu, Min},
title = {First-line nanoparticle polymeric micellar paclitaxel with gemcitabine in metastatic pancreatic cancer: a single-arm, prospective, and exploratory study},
journal = {Gastroenterology Report},
year = {2026},
volume = {14},
doi = {10.1093/gastro/goag034}
}
EUVIMED